Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Eaton Corporation plc (ETN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Eaton Corporation plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Eaton Corporation plc trades at $404.7 (market cap $158.15B). The key difference: Eaton Corporation plc is far larger — about 4× Alnylam Pharmaceuticals, Inc.'s market cap, and Eaton Corporation plc pays a 1.08% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ETN | |
|---|---|---|
Market Cap | $39.89B | $158.15B |
Sector | Health | Technology |
52-Week High | $491.22 | $435.78 |
52-Week Low | $278.09 | $315.82 |
Enterprise Value | $38.15B | $179.23B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Eaton (ETN) trades at $407.28, up 0.36% today, with a neutral technical stance and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.81 surpassing the $2.73 estimate. Fundamentals remain robust with a 36.89% gross margin and 20.87% ROE, though valuation multiples like the 39.85 P/E are elevated. Recent news highlights expansion in energy infrastructure and sustainability investments.
Outlook is positive given analyst consensus targets near $449.50 and zero sell ratings, but risks include high valuation sensitivity and projected 2026 cash flow pressure from increased investing activity. The stock offers growth exposure to power management and AI infrastructure trends, balanced by execution risks in a competitive industrial sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
